Incannex (ASX: IHL) partners with Procaps to develop cannabis medicine for clinical trial on sleep apnea
Cannabis Law Report
OCTOBER 26, 2021
to develop and manufacture soft gel capsules of Incannex’s cannabis medicine IHL-42X. The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. According to an article from the Lancet, sleep apnea affects 936 million adults globally.
Let's personalize your content